secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001171843-25-005262
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Harvard Bioscience Reports Q2 2025 Revenue of $20.5M, Net Loss of $2.3M, and Credit Amendment
--------------------------------------------------------------------------------

- Q2 2025 revenue of $20.5M vs $23.1M in Q2 2024; gross margin 56.4% vs 57.2%.
- Net loss improved to ($2.3M) from ($2.9M); adjusted EBITDA rose to $1.5M from $1.3M.
- Cash from operations was $2.8M, compared to ($0.8M) in Q2 2024.
- Credit agreement amended waiving defaults; new refinance deadline set for December 5, 2025.
- Q3 2025 revenue guidance $19M-$21M with gross margin 56%-58%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184325005262/0001171843-25-005262-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184325005262/f8k_080525.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005262

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer